Please login to the form below

Not currently logged in
Email:
Password:

Novel HIV treatment shows promise

Myriad Pharmaceuticals' HIV treatment MPC-4326 "safe and well tolerated"

Myriad Pharmaceuticals' HIV treatment MPC-4326 is safe and well tolerated according to two abstracts presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting on 12–15 September in San Francisco, US.

MPC-4326 is the first 'maturation inhibitor' a new class of HIV drug that inhibits the final step in the processing of the HIV Gag protein. Treatments with novel mechanism of action are though to be critical to combat drug resistance to available HIV therapies.

"I am very excited that the new 100 mg tablet formulation of MPC-4326 has performed so well," said Dr Adrian Hobden, President and CEO of the Salt Lake City-based biopharmaceutical company. "Coupled with the potential companion diagnostic and the significant viral load reductions seen in these two studies, we believe that we have a clear clinical path forward."

15th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics